First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen

Cancer Science

Volumn 103, Issue 1, 2012, Pages 150-153

  Takahashi, Norihiko ^a   Ohkuri, Takayuki ^b   Homma, Shigenori ^a   Ohtake, Junya ^b   Wakita, Daiko ^b   Togashi, Yuji ^c   Kitamura, Hidemitsu ^b   Todo, Satoru ^a,d   Nishimura, Takashi ^b  

^a HOKKAIDO UNIVERSITY   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

^c BioImmulance Co Ltd   (Japan)

^d HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; EPITOPE; GAMMA INTERFERON; HLA ANTIGEN; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G3; MELANOMA ANTIGEN 4; MONTANIDE ISA 51; PICIBANIL; TUMOR MARKER;

ADULT; ARTICLE; CANCER IMMUNIZATION; CANCER PATIENT; CASE REPORT; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COLON CANCER; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; ENZYME LINKED IMMUNOSPOT ASSAY; HELPER CELL; HUMAN; IMMUNE RESPONSE; IMMUNOHISTOLOGY; INJECTION SITE REACTION; KILLER CELL; LUNG METASTASIS; MALE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TH1 CELL; TUMOR GROWTH;

ANTIGENS, NEOPLASM; CANCER VACCINES; COLONIC NEOPLASMS; EPITOPES; HUMANS; IMMUNOTHERAPY, ACTIVE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PROGNOSIS; TH1 CELLS;

EID: 84855479007     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02106.x     Document Type: Article

References (19)

1. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumors: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
2. van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science 1991; 254: 1643-7.
3. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer 2005; 5: 615-25.
4. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nat Med 2004; 10: 909-15.
5. Hattori T, Mine T, Komatsu N et al. Immunological evaluation of personalized peptide vaccination in combination with UFT and UZEL for metastatic colorectal carcinoma patients. Cancer Immunol Immunother 2009; 58: 1843-52.
6. Noguchi M, Mine T, Komatsu N et al. Assessment of immunological biomarkers in patients with advanced cancer treated by personalized peptide vaccination. Cancer Biol Ther 2011; 10: 1266-79.
7. Nishikawa H, Kato T, Tawara I et al. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc Natl Acad Sci USA 2005; 102: 9253-7.
8. Nishimura T, Iwakabe K, Sekimoto M et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med 1999; 190: 617-27.
9. Takeshima T, Chamoto K, Wakita D et al. Local Radiation Therapy Inhibits Tumor Growth through the Generation of Tumor-Specific CTL: its Potentiation by Combination with Th1 Cell Therapy. Cancer Res 2010; 70: 2697-706.
10. Hunder NN, Wallen H, Cao J et al. Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med 2008; 358: 2698-703.
11. Kobayashi H, Celis E. Peptide epitope identification for tumor-reactive CD4 T cells. Curr Opin Immunol 2008; 20: 221-7.
12. Kenter GG, Welters MJ, Valentijn AR et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med 2009; 361: 1838-47.
13. Zwaveling S, Ferreira Mota SC, Nouta J et al. Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides. J Immunol 2002; 169: 350-8.
14. Speetjens FM, Kuppen PJ, Welters MJ et al. Induction of p53-specific immunity by a p53 synthetic long peptide vaccine in patients treated for metastatic colorectal cancer. Clin Cancer Res 2009; 15: 1086-95.
15. Leffers N, Vermeij R, Hoogeboom BN et al. Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer. Int J Cancer 2011; doi: 10.1002/ijc.25980 [Epub ahead of print].
16. Celis E, Center MSGotMCC. Overlapping human leukocyte antigen class I/II binding peptide vaccine for the treatment of patients with stage IV melanoma: evidence of systemic immune dysfunction. Cancer 2007; 110: 203-14.
17. Ohkuri T, Wakita D, Chamoto K, Togashi Y, Kitamura H, Nishimura T. Identification of novel helper epitopes of MAGE-A4 tumour antigen: useful tool for the propagation of Th1 cells. Br J Cancer 2009; 100: 1135-43.
18. Michaelsen TE, Garred P, Aase A. Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. Eur J Immunol 1991; 21: 11-6.
19. Bijker MS, van den Eeden SJ, Franken KL, Melief CJ, van der Burg SH, Offringa R. Superior induction of anti-tumor CTL immunity by extended peptide vaccines involves prolonged, DC-focused antigen presentation. Eur J Immunol 2008; 38: 1033-42.